Moreover, other reports have described PET tracers targeting prostate-specific membrane antigen (PSMA) and fibroblast activation protein inhibitor (FAPI) as useful for treatment response assessment and prognostic prediction in patients with HCC receiving immunotherapy, suggesting that PSMA- and FAPI-targeted PET could serve as complementary imaging modalities when combined with our imaging finding [14,15]. The gene discussed is FOLH1; the disease is hepatocellular carcinoma.